Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 12/20 | 0.79 |
| ▸ | ACHE | P22303 | 11/20 | 0.79 |
| ▸ | BCHE | P06276 | 9/20 | 0.79 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.68 |
| ▸ | RAD52 | P43351 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | UBE2N | P61088 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.57 |
| ▸ | PDE5A | O76074 | 1/20 | 0.56 |
| ▸ | CASP6 | P55212 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16280679 | 0.86 | ACHE (0.80) | APPACHEBCHERAD52KDM4E | |
| SCHEMBL21055815 | 0.85 | APP (0.59) | APPACHEBCHESLC2A1KDM4E | |
| SCHEMBL21055809 | 0.85 | ACHE (0.59) | APPACHEBCHESLC2A1LMNA | |
| SCHEMBL21055811 | 0.84 | APP (0.57) | APPACHEBCHESLC2A1ALDH1A1 | |
| SCHEMBL23747984 | 0.83 | APP (0.76) | APPACHEBCHESLC2A1RAD52 | |
| SCHEMBL8547756 | 0.83 | APP (0.76) | APPACHEBCHESLC2A1PDE5A | |
| SCHEMBL21055806 | 0.82 | GRK6 (0.56) | APPACHEBCHESLC2A1MAPT | |
| SCHEMBL9776812 | 0.81 | SLC2A1 (1.00) | APPACHEBCHESLC2A1 | |
| SCHEMBL8544714 | 0.81 | APP (0.72) | APPACHEBCHESLC2A1RAD52 | |
| SCHEMBL14869419 | 0.79 | APP (0.65) | APPACHEBCHESLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323007-B1 | N2N N4-disubstituted quinazoline-2,4-diamines and uses thereof | UNIVERSITY OF SOUTH FLORIDA (US) | 2019-06-18 | — | — | US | disclosed |
| US-10323007-B1 | N2N N4-disubstituted quinazoline-2,4-diamines and uses thereof | UNIVERSITY OF SOUTH FLORIDA (US) | 2019-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323007-B1 | N2N N4-disubstituted quinazoline-2,4-diamines and uses thereof | NQO2, NQO1, NIT2 | APP 742/4885ACHE 14/4885BCHE 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.